Phase 1 Dose Escalation Study of STM-416p administered intraoperatively to patients undergoing radical prostatectomy.
A Phase 1 trial with the primary objective of assessing the safety and tolerability of an immunotherapy investigational product administered intraoperatively to participants with prostate cancer undergoing radical prostatectomy, with the overall aim of therapy being reducing cancer recurrence.